[go: up one dir, main page]

BR0315264A - Comprimidos dispersáveis de deferasirox - Google Patents

Comprimidos dispersáveis de deferasirox

Info

Publication number
BR0315264A
BR0315264A BR0315264-2A BR0315264A BR0315264A BR 0315264 A BR0315264 A BR 0315264A BR 0315264 A BR0315264 A BR 0315264A BR 0315264 A BR0315264 A BR 0315264A
Authority
BR
Brazil
Prior art keywords
dispersible tablets
deferasirox
deferasirox dispersible
tablets
weight
Prior art date
Application number
BR0315264-2A
Other languages
English (en)
Inventor
Karine Deffez
Jean-Pierre Cassiere
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9945957&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0315264(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0315264A publication Critical patent/BR0315264A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)

Abstract

"COMPRIMIDOS DISPERSáVEIS DE DEFERASIROX". A invenção refere-se a comprimidos dispersáveis contendo ácido 4-[3,5-bis(2-hidroxifenil)-[1,2,4]triazoi-1-il]benzóico ou um sal farmaceuticamente aceitável do mesmo numa quantidade de 5 a 40% em peso do peso total do comprimido.
BR0315264-2A 2002-10-15 2003-10-14 Comprimidos dispersáveis de deferasirox BR0315264A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223978.8A GB0223978D0 (en) 2002-10-15 2002-10-15 Organic compound
PCT/EP2003/011351 WO2004035026A1 (en) 2002-10-15 2003-10-14 Deferacirox dispersible tablets

Publications (1)

Publication Number Publication Date
BR0315264A true BR0315264A (pt) 2005-08-23

Family

ID=9945957

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315264-2A BR0315264A (pt) 2002-10-15 2003-10-14 Comprimidos dispersáveis de deferasirox

Country Status (34)

Country Link
US (5) US20060110446A1 (pt)
EP (1) EP1556013B8 (pt)
JP (4) JP2006504748A (pt)
KR (1) KR100765580B1 (pt)
CN (2) CN1705471A (pt)
AR (1) AR041609A1 (pt)
AT (1) ATE431138T1 (pt)
AU (1) AU2003278078B2 (pt)
BR (1) BR0315264A (pt)
CA (1) CA2501659C (pt)
CY (1) CY1109902T1 (pt)
DE (1) DE60327646D1 (pt)
DK (1) DK1556013T3 (pt)
EC (1) ECSP055733A (pt)
EG (1) EG25453A (pt)
ES (1) ES2326167T3 (pt)
GB (1) GB0223978D0 (pt)
HK (1) HK1081101A1 (pt)
IL (1) IL167709A (pt)
JO (1) JO2700B1 (pt)
MX (1) MXPA05003999A (pt)
MY (1) MY140999A (pt)
NO (1) NO336958B1 (pt)
NZ (1) NZ539354A (pt)
PA (1) PA8586501A1 (pt)
PE (1) PE20040496A1 (pt)
PL (1) PL213325B1 (pt)
PT (1) PT1556013E (pt)
RU (1) RU2338532C2 (pt)
SI (1) SI1556013T1 (pt)
TN (1) TNSN05109A1 (pt)
TW (1) TWI339657B (pt)
WO (1) WO2004035026A1 (pt)
ZA (1) ZA200502488B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
AU2006303514B2 (en) * 2005-10-19 2010-06-24 Novartis Ag Dispersible tablets comprising deferasirox
KR20090007635A (ko) 2006-05-09 2009-01-19 노파르티스 아게 철 킬레이터 및 항-신생물 약제를 포함하는 조합물 및 그의용도
CL2007002026A1 (es) 2006-07-13 2008-06-06 Los Angeles Biomed Res Inst Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.
EP1994930A1 (en) 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
WO2009067557A1 (en) * 2007-11-19 2009-05-28 Teva Pharmaceutical Industries Ltd. Deferasirox pharmaceutical compositions
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
JPWO2010032489A1 (ja) 2008-09-22 2012-02-09 国立大学法人旭川医科大学 鉄キレート剤及びその製造方法、並びに鉄イオンの定量・捕捉方法
WO2010092419A1 (en) 2009-02-12 2010-08-19 Assistance Publique - Hopitaux De Paris Combined treatment of multiple sclerosis
NZ595271A (en) 2009-03-19 2013-08-30 Los Angeles Biomed Res Inst Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
EP2929877A1 (en) 2010-07-08 2015-10-14 ratiopharm GmbH Oral dosage form of deferasirox
MX2013003522A (es) 2010-10-01 2013-05-22 Cipla Ltd Composicion farmaceutica.
US9796605B2 (en) 2011-01-14 2017-10-24 Disease Adsorption System Technologies Co., Ltd. Polymeric iron chelating agent
CA2885394A1 (en) 2012-11-12 2014-05-15 Cipla Limited Fixed dose pharmaceutical composition comprising deferasirox and deferipone
RS58317B1 (sr) * 2013-03-08 2019-03-29 Novartis Ag Oralne formulacije deferasiroksa
MX2015015553A (es) * 2013-05-10 2016-06-17 Cipla Ltd Composicion farmceutica de dosis baja.
CN103735519A (zh) * 2014-01-10 2014-04-23 无锡万全医药技术有限公司 一种地拉罗司颗粒剂及其制备方法
EP2987482A1 (en) 2014-08-22 2016-02-24 Santa Farma Ilaç Sanayi A.S. Soluble and dispersible pharamaceutical deferasirox formulation
KR20160088965A (ko) * 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
WO2016167729A1 (en) 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
EP3095443A1 (en) 2015-05-21 2016-11-23 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Pharmaceutical composition comprising deferasirox
KR101695970B1 (ko) * 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
US20190091204A1 (en) 2016-03-17 2019-03-28 Lupin Limited Compositions of deferasirox
EP3248594A1 (en) * 2016-05-25 2017-11-29 ratiopharm GmbH Tablet for multiple oral applications
WO2018059922A1 (en) 2016-09-30 2018-04-05 Synthon B.V. Pharmaceutical composition comprising deferasirox
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
TR201707764A2 (tr) * 2017-05-29 2018-12-21 Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasiroksun bölünebilir tablet formları.
EP3675832A1 (en) 2017-09-01 2020-07-08 Jordan Sweden Medical and Sterilization Company Fast self dispersible dosage forms of deferasirox
WO2019108157A1 (en) * 2017-11-28 2019-06-06 Biofarma Ilac Sanayi Ve Ticaret A.S. A scored tablet formulation in a dispersible form comprising deferasirox
WO2019108156A1 (en) * 2017-11-28 2019-06-06 Biofarma Ilac Sanayi Ve Ticaret A.S. A scored tablet formulation comprising deferasirox in a film tablet form
TR201722910A2 (tr) * 2017-12-29 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasi̇roks i̇çeren suda dağilabi̇len tablet formülasyonlari
KR20190110771A (ko) 2018-03-21 2019-10-01 주식회사 한국팜비오 데페라시록스를 함유하는 소형 분산성 정제

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU120988A (en) * 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
YU183988A (en) * 1988-09-30 1990-08-31 Lek Tovarna Farmacevtskih Process for preparing dispersion pills of dihydroergotoxine
WO1992013527A1 (en) * 1991-01-30 1992-08-20 The Wellcome Foundation Limited Water-dispersible tablets
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
DE4412117A1 (de) * 1994-04-08 1995-10-12 Fette Wilhelm Gmbh Verfahren und Vorrichtung zum Aufbringen von pulverförmigem Schmier- oder Trennmittel auf die Preßwerkzeuge in Tablettiermaschinen
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
JP4117811B2 (ja) * 1997-04-22 2008-07-16 日本化薬株式会社 フルタミド製剤及びその製法
EP1070496A4 (en) * 1998-04-08 2004-07-21 Kyowa Hakko Kogyo Kk METHOD FOR PRODUCING TABLETS AND TABLET
JP2000063269A (ja) * 1998-08-20 2000-02-29 Taiho Yakuhin Kogyo Kk 固形製剤
JP2000086503A (ja) * 1998-09-07 2000-03-28 Pola Chem Ind Inc 錠剤医薬組成物
KR100720877B1 (ko) * 1998-12-28 2007-05-22 다케다 야쿠힌 고교 가부시키가이샤 비타민 제제
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
JP2002033764A (ja) * 2000-07-14 2002-01-31 Fujitsu Ltd 通信サービス提供システム、並びに通信サービス提供システムにおいて使用される移動端末装置、アドレスサーバ装置、およびルータ装置
JP4886107B2 (ja) * 2000-10-13 2012-02-29 サンスター株式会社 歯周病予防用口腔内溶解錠

Also Published As

Publication number Publication date
RU2338532C2 (ru) 2008-11-20
JP2014088417A (ja) 2014-05-15
US20120196909A1 (en) 2012-08-02
EP1556013B1 (en) 2009-05-13
JP2006504748A (ja) 2006-02-09
US20160175255A1 (en) 2016-06-23
US20110319457A1 (en) 2011-12-29
WO2004035026A1 (en) 2004-04-29
EP1556013B8 (en) 2010-03-03
PL213325B1 (pl) 2013-02-28
PA8586501A1 (es) 2005-02-04
ES2326167T3 (es) 2009-10-02
PE20040496A1 (es) 2004-09-20
CN1705471A (zh) 2005-12-07
CN101912391A (zh) 2010-12-15
TNSN05109A1 (en) 2007-05-14
NO336958B1 (no) 2015-12-07
CA2501659A1 (en) 2004-04-29
EP1556013A1 (en) 2005-07-27
AU2003278078B2 (en) 2007-08-02
TW200410949A (en) 2004-07-01
MXPA05003999A (es) 2005-06-22
CY1109902T1 (el) 2014-09-10
PT1556013E (pt) 2009-08-10
JP2016094435A (ja) 2016-05-26
JP5908505B2 (ja) 2016-04-26
KR20050071578A (ko) 2005-07-07
IL167709A (en) 2015-05-31
AR041609A1 (es) 2005-05-26
ZA200502488B (en) 2005-11-30
ECSP055733A (es) 2005-07-06
EG25453A (en) 2012-01-19
CA2501659C (en) 2011-08-23
ATE431138T1 (de) 2009-05-15
DK1556013T3 (da) 2009-08-17
AU2003278078A1 (en) 2004-05-04
GB0223978D0 (en) 2002-11-20
MY140999A (en) 2010-02-12
DE60327646D1 (de) 2009-06-25
PL375166A1 (en) 2005-11-28
US20110046193A1 (en) 2011-02-24
NO20052335L (no) 2005-07-15
TWI339657B (en) 2011-04-01
KR100765580B1 (ko) 2007-10-09
JO2700B1 (en) 2013-03-03
SI1556013T1 (sl) 2009-10-31
US20060110446A1 (en) 2006-05-25
RU2005114904A (ru) 2006-01-27
NO20052335D0 (no) 2005-05-12
HK1081101A1 (en) 2006-05-12
NZ539354A (en) 2007-04-27
JP2010031022A (ja) 2010-02-12

Similar Documents

Publication Publication Date Title
BR0315264A (pt) Comprimidos dispersáveis de deferasirox
MY136406A (en) High drug load tablet
BRPI0509645A (pt) comprimidos dispensáveis de deferasirox
TNSN04137A1 (fr) Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
NO20062004L (no) Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
EP1508570A4 (en) NEW PHYSIOLOGICAL ACTIVE SUBSTANCES
EP1630157A4 (en) ANTAGONIST OF CASR
ATE385768T1 (de) Hautpflegeverfahren gegen alterserscheinungen mit quaternären ammoniumsalzen als wirkstoffe
ATE400270T1 (de) Pharmazeutische zusammensetzungen mit sertaconazol für vaginale verwendung
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
MA33539B1 (fr) Comprimé
MXPA04002825A (es) Derivados de quinolina como antagonistas de neuropeptido y.
BR0111868A (pt) Composições farmacêuticas
BR9711414A (pt) Processo e composições farmacêuticas para abaixamento do nìvel de ácido úrico no organismo humano e para profilaxia da gota, hiperuricemia ou doença cardìaca coronária em humanos, e, uso de um composto
TNSN97039A1 (fr) Derives d'oxadiazole et de thiadiazole antagonistes des recepteurs muscariniques.
DE59610175D1 (de) Hydantoinderivate als zwischenprodukte für pharmazeutische wirkstoffe
AU3955199A (en) Remedies for itching containing PGD2 antagonists
FR2865732B1 (fr) Composes de type hydrazide et leur utilisation dans des compositions pharmaceutiques pour le traitement des maladies cardiovasculaires
BR0015333A (pt) Derivados de isoxazol como inibidores de fosfodiesterase vii
NO20013459D0 (no) Anvendelse av agiotensin II reseptorantagonister ved behandling av akutt myokardinfarkt
DE69812010D1 (de) 4-Aminopyrrole (3,2-d) Pyrimidinen als Antagonisten des Neuropeptide Y Receptors
BR0013749A (pt) Antagonistas dos receptores de vitronectina
ECSP034528A (es) Sales de sodio de 5-(4-(n-methyl-n-(2-piridil)amino)etoxi)bencil)tiazolidino-2,4-diona
BR0109196A (pt) Antagonistas dos receptores da il-18

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 13 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]